Method for cell-specific targeting

a cell-specific and targeting technology, applied in the field of cell-specific targeting, can solve the problems of limiting the use of currently known folate-mediated targeting methods in various medical applications, the risk of radiation injury in sensitive renal tissue, and the inability to exploit tumour-targeting for its use in radiotherapy, so as to reduce the burden of unwanted doses and precise localisation of malignant cell populations

Active Publication Date: 2007-12-06
MERCK & CIE KG
View PDF2 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0015]In a further aspect, the present invention provides a method for diagnostic imaging of a cell or population of cells expressing a folate-receptor, said method comprising the steps of: administering an antifolate in effective amounts, followed by administering a folate / pteroate-conjugate comprising a diagnostic agent in effective amounts to allow binding) to occur, and obtaining a diagnostic image of said cell or population of cells using Nuclear Medicine (single photon emission tomography (SPECT), or positron emission tomography (PET)) or Magnetic Resonance imaging techniques (FIG. 2). Consequently improved target-to-non-target ratios can be achieved enabling the more precise localisation of malignant cell populations and reducing unwanted dose burden to healthy tissue and organs (FIG. 3-6). Alternatively said method comprises the steps of administering a folate / pteroate-conjugate comprising a diagnostic agent in effective amounts, followed by administering an antifolate in effective amounts. More alternatively said method comprises administering a folate / pteroate-conjugate comprising a diagnostic agent in effective amounts, simultaneously with an antifolate in effective amounts.

Problems solved by technology

This issue severely limit the use of currently known folate-mediated targeting methods in various medical applications and in particular the use of therapeutic folate / pteroate-conjugates radiolabeled with particle-emitting radioisotopes (β− or α), since application of high radioactivity in order to achieve a cytotoxic radiation dose in tumour cells would consequently comprise the risk of radiation injury in sensitive renal tissue.
Therefore, FR tumour-targeting has not been exploited for its use in radiotherapy so far.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for cell-specific targeting
  • Method for cell-specific targeting
  • Method for cell-specific targeting

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0063]Materials and Methods. The synthesis of the picolylamine monoacetic acid (PAMA)-folate-conjugate was performed as described in (Müller et al, J. Organomet. Chem. 2004, 689:4712-21). Precursor [99mTc(CO)3(OH2)3]+was prepared using the Isolink™-kit (Mallinckrodt-Tyco, Petten, the Netherlands) (Alberto et al, J. Organomet. Chem. 1995, 492:217-24; Alberto et al, J. Am. Chem. Soc. 2001; 123:3135-36). [Na][99mTcO4] was eluted from a 99Mo / 99mTc-generator (Mallinckrodt-Tyco, Petten, the Netherlands) with a 0.9% saline solution. [Na][188ReO4] was eluted from a 188W / 188Re-generator (Oak Ridge National Laboratories, Oak Ridge, Tenn.). Injection solutions of methotrexate (Amersham Life Science) were prepared with phosphate buffered saline (PBS, pH 7.4) followed by sterile flirtation. The injection solutions of Tomudex® (ralitrexed) and Alimta® (pemetrexed) were prepared according to the package instructions with aqua ad injectabilia or NaCl 0.9% respectively. KB cells (CCL-17) were purcha...

example 2

In Vivo Evaluation of Different Folate Radiotracers (2a, 3a) in Combination with MTX and PMX Respectively

[0081]The effect of antifolates with respect to selective protection of kidney tissue is not limited to compound 1a / b but is applicable to structurally different complexes as mentioned above including e.g. complexes 2a and 3a. Biodistribution of the radiotracers 2a and 3a were assessed in mice, with or without pre-treated with PMX or MTX respectively, 1 h previous to the injection of the radiotracer (Table 6).

TABLE 5Biodistribution 4 h p.i. data of radiotracer 2a and 3a in athymic nude mice, bearingKB xenografts with or without PMX or MTX pre-treatment.Organs2a2a + PMXa3a3a + MTXablood0.19 ± 0.180.07 ± 0.020.03 ± 0.010.01 ± 0.00heart0.80 ± 0.600.72 ± 0.390.20 ± 0.090.02 ± 0.00lung0.85 ± 0.080.50 ± 0.190.20 ± 0.020.02 ± 0.00spleen0.30 ± 0.050.19 ± 0.030.08 ± 0.020.01 ± 0.00kidney42.02 ± 7.31 5.05 ± 0.677.11 ± 0.750.78 ± 0.17stomach0.62 ± 0.220.46 ± 0.220.54 ± 0.580.14 ± 0.06intest...

example 3

In Vivo Evaluation of 99mTc(CO)3-Folate (1a) in Combination with MTX Using Different Folate Receptor Positive Tumour Cell Xenografts

[0082]The effect of antifolates with respect to selective protection of kidney tissue is not limited to KB cancer cells but to all cell lines expressing the folate receptor and activated (but not resting) synovial macrophages.

[0083]4-5-week-old female, athymic nude mice (CD1-Foxn1 / nu) were purchased from Charles River Laboratories (Sulzfeld, Germany). Mice were housed under conditions of controlled temperature (26° C.), humidity (68%) and daily light cycle (12 h light / 12 h dark). The animals were fed with a folate-deficient rodent diet (to reduce their serum folate to a level near that of humans) (Mathias et al, J. Nucl. Med. 1996; 37:1003-08). After an acclimation period of 5-7 days, the mice were inoculated subcutaneously with the tumour cell suspension using IGROV-1 and KB-V1 (multiresistant) cells (5×106 cells) into the subcutis of the axilla. Radio...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Timeaaaaaaaaaa
Molar densityaaaaaaaaaa
Fractionaaaaaaaaaa
Login to view more

Abstract

Method for selective targeting of one or more effector moiety such as diagnostic or a therapeutic agent to a cell or population of cells expressing a folate-receptor comprising simultaneous or sequential administration of an antifolate with a folate- or pteroate-conjugate comprising said one or more effector moiety.

Description

FIELD OF THE INVENTION[0001]The present invention relates to a method for selective protection of human healthy, normal tissue expressing folate receptors while enhancing targeting of a cell or populations of cells expressing folate-receptors of the type alpha, beta and gamma or activated (but not resting) synovial macrophages, and its use in diagnostic and therapeutic medical applications, for example diagnostic imaging, radiotherapy, boron neutron capture therapy, chemotherapy. In particular selective protecting is achieved by simultaneous or sequential administration of an antifolate with a folate- or pteroate-conjugate comprising one or more effector moieties.BACKGROUND OF THE INVENTION[0002]Cell-specific targeting for delivery of effector moieties such as diagnostic or therapeutic agents is a widely researched field and has led to the development of non-invasive diagnostic and / or therapeutic medical applications. In particular in the field of nuclear medicine procedures and tre...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61N5/00A61K51/00A61K31/525A61K31/22A61K48/00A61K38/17
CPCA61K31/22A61K51/0459A61K48/00A61K31/525
Inventor MOSER, RUDOLFGROEHN, VIOLASCHIBLI, ROGERMUELLER, CRISTINA MAGDALENA
Owner MERCK & CIE KG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap